Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com

Dow Jones

03/09

By George Glover

Hims & Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with Novo Nordisk, the Danish drugmaker that sells Ozempic and Wegovy.

Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&P 500 slumped 0.8% after the Iran war triggered a surge in oil prices.

Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter.

Novo and Hims didn't immediately respond to requests for comment from Barron's.

Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy.

Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called "knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process."

The report of the truce comes at a time when both stocks have been struggling.

Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall.

Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny.

Write to George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 09, 2026 06:33 ET (10:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2618605647"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618605647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618605647?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618605647","market":"other","top_or_hot":-1,"title":"Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Hims &amp; Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the Danish drugmaker that sells Ozempic and Wegovy. \n</p>\n<p>\n  Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&amp;P 500 slumped 0.8% after the Iran war triggered a surge in oil prices. \n</p>\n<p>\n  Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter. \n</p>\n<p>\n  Novo and Hims didn't immediately respond to requests for comment from Barron's. \n</p>\n<p>\n  Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy. \n</p>\n<p>\n  Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\" \n</p>\n<p>\n  The report of the truce comes at a time when both stocks have been struggling. \n</p>\n<p>\n  Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall. \n</p>\n<p>\n  Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-09 18:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Hims &amp; Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the Danish drugmaker that sells Ozempic and Wegovy. \n</p>\n<p>\n  Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&amp;P 500 slumped 0.8% after the Iran war triggered a surge in oil prices. \n</p>\n<p>\n  Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter. \n</p>\n<p>\n  Novo and Hims didn't immediately respond to requests for comment from Barron's. \n</p>\n<p>\n  Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy. \n</p>\n<p>\n  Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\" \n</p>\n<p>\n  The report of the truce comes at a time when both stocks have been struggling. \n</p>\n<p>\n  Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall. \n</p>\n<p>\n  Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618605647","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618605647","pubTimestamp":1773052380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with Novo Nordisk, the Danish drugmaker that sells Ozempic and Wegovy.Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&P 500 slumped 0.8% after the Iran war triggered a surge in oil prices.Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter.Novo and Hims didn't immediately respond to requests for comment from Barron's.Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy.Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\". ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","BK4588":"碎股","NVOX":"2倍做多NVO ETF-Defiance","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","BK4196":"保健护理服务","BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4599":"减肥药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF","NVOH":"Novo Nordisk A/S B Shares ADRhedged","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMS":"Hims & Hers Health Inc."},"translate_title":"Hims&Hers股价飙升54%。报道称，该公司已与诺和诺德达成休战协议。——Barrons.com","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIYY":0.6,"NVO":1.95,"HIMS":1.97,"HIMZ":0.6,"HIMY":0.6,"NVOX":0.6,"NVOH":0.6,"HMYY":0.6},"content_text":"By George Glover \n\n\n  Hims & Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with Novo Nordisk, the Danish drugmaker that sells Ozempic and Wegovy. \n\n\n  Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&P 500 slumped 0.8% after the Iran war triggered a surge in oil prices. \n\n\n  Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter. \n\n\n  Novo and Hims didn't immediately respond to requests for comment from Barron's. \n\n\n  Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy. \n\n\n  Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\" \n\n\n  The report of the truce comes at a time when both stocks have been struggling. \n\n\n  Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall. \n\n\n  Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny. \n\n\n  Write to George Glover at george.glover@dowjones.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:33 ET (10:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}